Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy

Journal of Human Genetics

Volumn 51, Issue 3, 2006, Pages 155-160

  Lu, Jian Wei ^a   Gao, Chang Ming ^a   Wu, Jian Zhong ^a   Cao, Hai Xia ^a   Tajima, Kazuo ^b   Feng, Ji Feng ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Genotypes; Stomach neoplasms; Thymidylate synthase

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINATE CALCIUM; OXALIPLATIN; PACLITAXEL; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; PRIMER DNA;

3' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DRUG SENSITIVITY; FEMALE; GENOTYPE; HUMAN; LEUKOCYTE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MUCOSA INFLAMMATION; NEURITIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH CANCER; VOMITING; AGED; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; STOMACH TUMOR;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 33645213805     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-005-0339-4     Document Type: Article

References (20)

1. Ajani JA (2002) Docetaxel for gastric and esophageal carcinomas. Oncology 16:89-96
2. Berardi R, Scartozzi M, Romagnoli E, Antognoli S, Cascinu S (2004) Gastric cancer treatment: a systematic review. Oncol Rep 11:911-916
3. Calascibetta A, Cabibi D, Martorana A, Sanguedolce G, Rausa L, Feo S, Dardanoni G, Sanguedolce R (2004) Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res 24:3875-3880
4. Coombes RC, Chilvers CE, Amadori D, Medi F, Fountzilas G, Rauschecker H, Vassilopoulos P, Ferreira EP, Vannozzi G, Bliss JM et al (1994) Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Ann Oncol 5:33-36
5. Findlay M, Cunningham D (1993) Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 19:29-44
6. Gao CM, Takezaki T, Wu JZ, Liu YT, Ding JH, Li SP, Su P, Hu X, Kai HT, Li ZY, Matsuo K, Hamajima N, Sugimura H, Tajima K (2004) Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. Asian Pac J Cancer Prev 5:133-138
7. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197
8. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813-3818
9. Kohne CH, Wils JA, Wilke HJ (2000) Developments in the treatment of gastric cancer in Europe. Oncology 14:22-25
10. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458-462
11. Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880-5888
12. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunei R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A (2002) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543-4548
13. Mandela MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319-327
14. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310-312
15. Merkelbach-Bruse S, Hans V, Mathiak M, Sanguedolce R, Alessandro R, Ruschoff J, Buttner R, Houshdaran F, Gullotti L (2004) Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. Oncol Rep 11:839-843
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
17. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827-841
18. Tsai JY, Safran H (2003) Status of treatment for advanced gastric carcinoma. Curr Oncol Rep 5:210-218
19. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD (2000) Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9:1381-1385
20. Zhang Z, Xu Y, Zhou J, Wang X, Wang L, Hu X, Guo J, Wei Q, Shen H (2005) Polymorphisms of thymidylate synthase in the 5′- and 3′-untranslated regions associated with risk of gastric cancer in South China: a case-control analysis. Carcinogenesis 26:1764-1769